The Vaccine Contract Manufacturing Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The global market report for vaccine contract manufacturing experienced a substantial growth trend. The market size increased from $3.58 billion in 2024 to $3.93 billion in 2025, marking a compound annual growth rate (CAGR) of 9.7%.
The Vaccine Contract Manufacturing Global Market is expected to reach a market size of $5.93 billion in 2029, growing at a compound annual growth rate (CAGR) of 10.8%.
Download Your Free Sample of the 2025 Vaccine Contract Manufacturing Market Report and Uncover Key Trends Now!The key drivers in the vaccine contract manufacturing market are:
• Growing emphasis on pandemic preparedness
• Increased outsourcing in pharmaceutical manufacturing
• Expansion of biopharmaceutical companies
• Accelerated vaccine development timelines
The vaccine contract manufacturing market covered in this report is segmented –
1) By Service Type: Fill-Finish, Bulk Product
2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines
3) By Process: Downstream, Upstream
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By End-Use: Human Use, Veterinary
The key trends in the vaccine contract manufacturing market are:
• Integration of single-use technologies in vaccine manufacturing is an emerging trend.
• The rise in personalized medicine approaches to vaccine development is noteworthy.
• The development of mRNA and viral vector vaccines is shaping the future of the market.
• There is an ongoing trend of adopting continuous manufacturing processes and expanding fill-finish services.
The major players in the vaccine contract manufacturing market are:
• Pfizer Inc
North America was the largest region in the vaccine contract manufacturing market in 2024